GlobeNewswire by notified

Roche announces PathAI collaboration for artificial intelligence-based digital pathology applications for improved patient care

Share
  • Artificial Intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatment.
  • Collaboration with PathAI expands pathologist access to innovative AI-powered technology to support companion diagnostic and drug development programs.
  • Builds on Roche’s Digital Pathology Open Environment, expanding the company’s commitment to improving patient outcomes and advancing personalised healthcare through innovation

Basel, 15 October 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has entered an agreement with PathAI, a global leader in artificial intelligence (AI)-powered technology for pathology. Under the development and distribution agreement, the companies will jointly develop an embedded image analysis workflow for pathologists. This workflow will allow PathAI image analysis algorithms to be accessed within NAVIFY Digital Pathology, the cloud version of Roche’s uPath enterprise software. This collaboration is now possible through Roche’s Digital Pathology Open Environment, which allows pathologists to securely access third-party AI-powered technology alongside Roche’s growing menu of AI-based image analysis tools.

This agreement with PathAI is among the first to expand digital tools through the Roche open environment, and is one of the first for PathAI to distribute its AI-powered solutions via a third party platform.

“Working together, Roche and PathAI will bring the latest leading technologies to pathologists through our digital pathology solution. Expanded access to a menu of high medical value digital diagnostic tools will further ensure that patients are accurately diagnosed and receive the most effective treatment available,” said Thomas Schinecker, CEO Roche Diagnostics.

Roche will initially distribute PathAI-developed research-use-only (RUO) algorithms through NAVIFY Digital Pathology, spanning multiple cancer types. The combined innovation will expand support for healthcare companies’ companion diagnostic and drug development programs.

“This collaboration brings together all of the components required to deliver and commercialise a differentiated AI-based digital pathology medical device including assay, scanner, image management system and algorithm. We believe this partnership will unlock the potential for digital pathology in the companion diagnostics setting, offering a differentiated service to biopharma sponsors and ultimately new opportunities to improve patient outcomes,” said Dr. Andy Beck, CEO of PathAI.

About Roche Digital Pathology
As the leading provider of pathology lab solutions, Roche is delivering an end-to-end digital pathology solution from tissue staining to producing high-quality digital images that can be reliably assessed using automated clinical image analysis algorithms.

Whole slide imaging combined with modern artificial intelligence (AI)-based image analysis tools have the potential to transform the practice of pathology. The use of AI and deep learning methods to interpret whole slide images in digital pathology enables pathologists to derive novel and meaningful diagnostic insights from tissue samples. AI-based image analysis automates quantitative tasks and enables fast, repeatable evaluation of information-rich tissue images that are sometimes difficult to interpret manually. AI-based image analysis uncovers aspects that are invisible to the human eye and reduces the risk of human error. Patients, whose tissue samples are analysed using AI-based image analysis, can benefit from a faster and more accurate diagnosis. The insights gained from these analyses can help pathologists determine the best treatment option for cancer patients.

Roche offers two deployment options for its uPath software: an on-premise solution and a cloud solution, marketed as NAVIFY Digital Pathology. The VENTANA DP 200 slide scanner and Roche uPath enterprise software are CE-IVD marked for in-vitro diagnostic use and are available in the U.S. for research use only (RUO). Image analysis algorithms developed by third-party entities and their utilisation are the responsibility of the third party provider.

About Roche
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics, as well as growing capabilities in the area of data-driven medical insights help Roche deliver truly personalised healthcare. Roche is working with partners across the healthcare sector to provide the best care for each person.

Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.


Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

Dr. Nicolas Dunant
Phone: +41 61 687 05 17
Patrick Barth
Phone: +41 61 688 44 86

Dr. Barbara von Schnurbein
Phone: +41 61 687 89 67
Karsten Kleine
Phone: +41 61 682 28 31

Nina Mählitz
Phone: +41 79 327 54 74

Sileia Urech
Phone: +41 79 935 81 48
Nathalie Meetz
Phone: +41 61 687 43 05










Roche Investor Relations
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com
Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com

Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com

Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
Investor Relations North America

Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Wolters Kluwer completes divestment U.S. legal education business1.12.2021 17:35:00 CET | Press release

Wolters Kluwer completes divestment U.S. legal education business December 1, 2021 — Wolters Kluwer today announces that it has completed the divestment of its U.S. legal education business to Transom Capital Group. As previously announced on September 27, Wolters Kluwer intends to deploy the post-tax proceeds towards additional share repurchases in order to mitigate the expected dilution to adjusted earnings per share from the sale. To this end, Wolters Kluwer has now granted a mandate to a third-party to execute up to €60 million in share buybacks on our behalf in the remainder of this year (the period starting December 2, 2021, up to and including December 29, 2021). Including this mandate, when completed, total share repurchases will reach €410 million in 2021. This mandate is governed by the limits of relevant laws and regulations (in particular Regulation (EU) 596/2014) and Wolters Kluwer’s Articles of Association. Repurchased shares are added to and held as treasury shares and a

HMNC Brain Health to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference1.12.2021 16:37:31 CET | Press release

MUNICH, Germany, Dec. 01, 2021 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a clinical stage biopharma company pioneering the development of personalized therapies powered by predictive companion diagnostics, announced today that Chief Executive Officer, Benedikt von Braunmühl, Chief Clinical Development Officer, Dr. Hans Eriksson and Head of Operations, Dr. Maximilian Döbler will present at H.C. Wainwright’s 2nd Annual Psychedelics Conference on Monday, December 6th, 2021. In addition, Dr. Eriksson will participate in the ‘Future of Mental Healthcare’ panel at 2:30 p.m. Eastern Time. To attend, please register here. HMNC Brain Health’s virtual presentation will be available beginning Monday, December 6th at 7:00 a.m. Eastern Time and is accessible through the following webcast link: https://journey.ct.events/view/d77f2d7d-bff2-4d9a-8e89-620a24d1f35a. A webcast of the presentation will be available on the HMNC Brain Health Website for 90 days through the above webca

4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab1.12.2021 15:03:00 CET | Press release

AGC Biologics to produce Procizumab for early and late clinical phases at company’s Chiba and Copenhagen facilities Seattle, Dec. 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The first-in-class monoclonal antibody Procizumab offers a new approach for the treatment of life-threatening diseases related to acute circulatory failure. Under the terms of the agreement, the companies will collaborate to transfer and optimize the manufacturing process for Procizumab. AGC Biologics will manufacture the clinical trial materials at its site in Chiba and transfer to its Copenhagen facility for all late phase activities including commercialization, to support early and late clinical phases and launch readiness of 4TEEN4’s monoclonal antibody. “We look forward to partnering with 4TEEN4

Kalmar’s proven straddle carrier technology to enhance operational capabilities at Kingston Freeport Terminal, Jamaica1.12.2021 15:00:00 CET | Press release

CARGOTEC CORPORATION, PRESS RELEASE, 1 DECEMBER 2021 AT 4 PM (EET) Kalmar, part of Cargotec, has signed a contract to supply the Kingston Freeport Terminal Limited (KFTL) with four diesel-electric straddle carriers for use at their terminal in Kingston, Jamaica. The order was booked in Cargotec's 2021 Q4 order intake with delivery scheduled to be completed during Q3 2022. KFTL is a strategic transhipment hub in the Caribbean, located at the exit of the Panama Canal and the crossroads of the North/South and East/West lines. The terminal was established in 2015, and it is part of Terminal Link, a joint venture between The CMA CGM Group, a world leader in shipping and logistics, and China Merchants Port (CMP). The four Kalmar Straddle Carriers are part of a progressive fleet renewal strategy geared to improve performance and reliability in the terminal's operation. KFTL’s equipment fleet already includes Kalmar straddle carriers, reachstackers, empty container handlers and terminal tracto

Sinch carries out second part of the directed new share issue of approximately 40 million shares announced on 30 September 20211.12.2021 14:50:00 CET | Press release

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, SOUTH AFRICA, NEW ZEALAND, HONG KONG, SINGAPORE OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE MAY BE UNLAWFUL, WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES Stockholm, Sweden – December 1, 2021 - Sinch AB (publ) (“Sinch” or the “Company”) carries out a directed new share issue through the issuance of 21 million new shares for a total consideration of approximately SEK 3,469 million. The new share issue constitutes the second part of the SEK 6.6 billion new share issue of in total 40,077,841 shares (the “Shares”) announced on 30 September 2021, the proceeds of which are used to partially fund the acquisition of Pathwire. The subscribers consisted of institutional investors, among others the Canada Pension Plan Investment Board (“CPP Investments”), Temasek, SeaTown Master Fund (“SeaTown”), and SB Northstar LP,

Sinch genomför den andra delen av den riktade nyemissionen om cirka 40 miljoner aktier som offentliggjordes den 30 september 20211.12.2021 14:50:00 CET | Pressemelding

EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUERING ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, KANADA, JAPAN, AUSTRALIEN, SYDAFRIKA, NYA ZEELAND, HONGKONG, SINGAPORE ELLER I NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTIONEN ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE KUNNA VARA OLAGLIG, KRÄVA YTTERLIGARE REGISTRERING ELLER ANDRA ÅTGÄRDER Stockholm, Sverige – 1 december 2021 – Sinch AB (publ) (“Sinch” eller “Bolaget”) genomför en riktad nyemission av 21 miljoner aktier mot en total teckningslikvid om cirka 3,469 miljarder kronor. Nyemissionen utgör den andra delen av den riktade nyemissionen om totalt cirka 6,6 miljarder kronor av 40 077 841 aktier (”Aktierna”) som offentliggjordes den 30 september 2021. Emissionslikviden från den riktade nyemissionen används för att delfinansiera förvärvet av Pathwire. Tecknarna bestod av institutionella investerare, däribland Canada Pension Plan Investment Board (”CPP Investments”), Temasek, SeaTown Master Fund (”Seatown

Voyager Closes Series A Funding, Marking $10M Raised1.12.2021 14:00:00 CET | Press release

Investment to fuel growth across the marine supply chain HOUSTON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Voyager Portal, a software platform enabling companies to reduce cost, risk, and complexity in their marine supply chain, has today announced an $8.4 million Series A investment, led by Phaze Ventures. Other new investors include ScOp Venture Capital, Waybury Capital and Flexport. All existing investors followed in on this round. The new funding comes on the back of unprecedented growth since the company raised $1.5 million in seed money two years ago. Since then, revenue has increased 13x from Q3 2020 to Q3 2021 and was up 40% from Q2 2021. Additionally, Voyager surpassed the $1 billion-mark for freight managed on the platform. Voyager's customers include manufacturers, traders and shippers in the renewable energy, commodity trading, mining and petrochemicals industries. “Voyager Portal was created to significantly reduce cost, risk, and complexity when transporting bulk materials aroun